MDLN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Medline Inc (MDLN) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock has strong analyst support, positive long-term growth prospects, and a compelling setup into fiscal 2026. Despite some short-term financial challenges, the company's fundamentals and analyst sentiment suggest meaningful upside potential.
The technical indicators are neutral to slightly bullish. The RSI is neutral at 58.378, and the MACD is below 0 but negatively contracting, suggesting potential stabilization. The stock is trading near key resistance levels (R1: 44.03), with support at 42.59. The stock's recent price increase of 3.15% in regular market hours indicates positive momentum.
Strong analyst ratings with multiple price target increases, including Citi's $60 target and JPMorgan's $53 target.
Q4 revenue growth of 14.78% YoY and positive guidance for fiscal
High implied volatility percentile (81.36), indicating strong interest in the stock.
Potential 8.08% upside in the next month based on candlestick pattern analysis.
Decline in net income (-37.02% YoY) and EPS (-36.36% YoY) in Q4
Gross margin dropped to 22.32%, down 9.56% YoY.
No recent news or congress trading data to act as additional catalysts.
In Q4 2025, Medline's revenue increased by 14.78% YoY to $7.79 billion, showcasing strong topline growth. However, net income dropped by 37.02% YoY to $182 million, and EPS declined by 36.36% YoY to $0.14. Gross margin also decreased to 22.32%, reflecting pressure on profitability.
Analysts are overwhelmingly positive on MDLN, with multiple Buy ratings and price target increases. Notable targets include Citi's $60, Tigress Financial's $60, and JPMorgan's $53. Analysts highlight Medline's durable growth levers, margin expansion, and strong 2026 guidance as key drivers for upside.
